Coya Therapeutics (COYA) Share-based Compensation (2021 - 2026)

Coya Therapeutics has disclosed Share-based Compensation across 6 years of filings, most recently posting $5.4 million for Q2 2026.

• In Q2 2026, Share-based Compensation rose 82.2% year-over-year to $5.4 million; the TTM figure through Jun 2026 stood at $5.4 million (up 82.2% YoY), while the FY2025 annual figure was $5.1 million, down 5.56% from the prior year.
• Share-based Compensation came in at $5.4 million for Q2 2026 at Coya Therapeutics, down from $7.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $7.3 million in Q1 2026 to a low of $21425.0 in Q1 2022.
• Average Share-based Compensation over 5 years is $2.1 million, with a median of $1.2 million recorded in 2023.
• Year-over-year, Share-based Compensation slumped 79.9% in 2022 and jumped 4635.32% in 2023.
• Over 5 years, Share-based Compensation stood at $71429.0 in 2022, then jumped by 233.2% to $237999.0 in 2023, then surged by 232.16% to $790549.0 in 2024, then surged by 39.6% to $1.1 million in 2025, then surged by 389.3% to $5.4 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $5.4 million in Q2 2026, $7.3 million in Q1 2026, and $1.1 million in Q4 2025.